Medistem Laboratories, Inc. (MDSM.OB) is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem’s corporate mission is to transform these stem cells into valuable medical treatments.
The Company’s business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients while seeking to commercialize products in the U.S. market. Medistem’s proprietary technology is based on adult stem cells sourced from umbilical cords, fat, bone marrow, and muscle, and is used Medistem’s licensee ICM in the treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases.
Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions. This positions the company to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings.
The global market for stem cell treatments and therapies is expected to have substantial growth from its market value of $24.6 billion in 2005 to reach $68.9 billion in 2010. These findings are according to the biopharma research firm, Piribo. Overseas, stem cell therapy centers have increased rapidly due to less stringent regulations in comparison to US regulations.
Let us hear your thoughts: Medistem Laboratories, Inc. Message Board